HIGHLY SELECTIVE ACTIVITY OF MDM2 INHIBITOR RG7112 AGAINST MDM2-AMPLIFIED/TP53 WILD-TYPE GLIOBLASTOMAS

被引：0
作者：
Verreault, Maite [1 ,2 ,3 ,4 ]
Levasseur, Camille [1 ,2 ,3 ,4 ]
Schmitt, Charlotte [1 ,2 ,3 ,4 ]
Guehennec, Jeremy [1 ,2 ,3 ,4 ]
Labussiere, Marianne [1 ,2 ,3 ,4 ]
Marie, Yannick [1 ,2 ,3 ,4 ]
Haidar, Sam [5 ,6 ]
Mokhtari, Karima [1 ,2 ,3 ,4 ,7 ]
Hoang-Xuan, Khe [1 ,2 ,3 ,4 ,7 ]
Sanson, Marc [1 ,2 ,3 ,4 ,7 ]
Ligon, Keith [5 ,6 ]
Delattre, Jean-Yves [1 ,2 ,3 ,4 ,7 ]
Idbaih, Ahmed [1 ,2 ,3 ,4 ,7 ]
机构：
[1] INSERM, U1127, F-7501 Paris, France
[2] CNRS, UMR 7225, F-75013 Paris, France
[3] Univ Paris 06, Sorbonne Univ, UMR S 1127, F-75013 Paris, France
[4] ICM, F-750133 Paris, France
[5] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Dept Med Oncol, Boston, MA 02115 USA
[6] Brigham & Womens Hosp & Childrens, Div Neuropathol, Dept Pathol, Boston, MA USA
[7] Hop La Pitie Salpetriere, AP HP, Serv Neuropathol R Escourolle, Serv Neurol, F-75013 Paris, France
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
10.1093/neuonc/nou255.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ET-62
引用
收藏
页数：1
相关论文
共 50 条
  • [21] TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas
    Della Torre, G
    Pasquini, G
    Pilotti, S
    Alasio, L
    Civelli, E
    Cozzi, G
    Milella, M
    Salvetti, M
    Pierotti, MA
    Severini, A
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2000, 9 (01) : 41 - 46
  • [22] Activating TP53 by Dual Inhibition of MDMX and MDM2
    Steidl, Ulrich G.
    BLOOD, 2019, 134
  • [23] Analysis of MDM2 and TP53 genes in canine liposarcoma
    Muscatello, Luisa Vera
    de Biase, Dario
    Maloberti, Thais
    di Oto, Enrico
    Tallini, Giovanni
    Pellegrino, Valeria
    Bacci, Barbara
    Roccabianca, Paola
    Lepri, Elvio
    Crippa, Luca
    Avallone, Giancarlo
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [24] Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53
    Dumbrava, Ecaterina E.
    Iwamoto, Fabio M.
    Agulnik, Mark
    Milhem, Mohammed
    Tolcher, Anthony W.
    Chugh, Rashmi
    Demeure, Michael J.
    Mita, Alain
    Demel, Kurt
    Diamond, Mark
    Mirakhur, Beloo
    Wilson, Laksmi
    Oganesian, Aram
    Chan, Danna
    Keer, Harold N.
    Taylor, Jason
    Sims, Martin J.
    Biondo, Andrea
    Jueliger, Simone
    Spira, Alexander
    CANCER RESEARCH, 2024, 84 (07)
  • [25] Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells
    Mir, Roser
    Tortosa, Avelina
    Martinez-Soler, Fina
    Vidal, August
    Condom, Enric
    Perez-Perarnau, Alba
    Ruiz-Larroya, Tatiana
    Gil, Joan
    Gimenez-Bonafe, Pepita
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (07) : 1525 - 1536
  • [26] Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)
    Nimmagadda, Subbaiah Chary
    Patnana, Pradeep Kumar
    Budde, Paulina Marie
    Ahmed, Helal
    Covey, Todd
    Krejsa, Cecile
    Rothbaum, Wayne
    Von Bubnoff, Nikolas
    Khandanpour, Cyrus
    BLOOD, 2023, 142
  • [27] Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cell lines
    Ananthapadmanabhan, Varsha
    Knott, Aine
    Soroko, Kara M.
    Gokhale, Prafulla C.
    Tirunagaru, Vijaya
    Doebele, Robert
    DeCaprio, James A.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [28] The MDM2 and CDKN2A Copy-number-variation Influence the TP53-signature-score in Wild-type TP53 Luminal Type Breast Cancer
    Han, Min
    Yamaguchi, Shigeo
    Onishi, Mai
    Fujii, Tomoaki
    Hosoya, Masaki
    Wen, Xuan
    Kido, Hidenori
    Kato, Shunsuke
    ANTICANCER RESEARCH, 2022, 42 (05) : 2277 - 2288
  • [29] Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine
    Yee, Karen
    Martinelli, Giovanni
    Assouline, Sarit
    Kasner, Margaret
    Vey, Norbert
    Kelly, Kevin R.
    Drummond, Mark W.
    Dennis, Michael
    Seiter, Karen
    Blotner, Steven
    Jukofskyn, Lori
    Middleton, Steven
    Zhi, Jianguo
    Chen, Gong
    Zhong, Hua
    Nichols, Gwen
    BLOOD, 2013, 122 (21)
  • [30] Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma
    Patel, Heena
    Polanco-Echeverry, Guadalupe
    Segditsas, Stefania
    Volikos, Emmanouil
    McCart, Amy
    Lai, Cecilia
    Guenther, Thomas
    Zaitoun, Abed
    Sieber, Oliver
    Ilyas, Mohammed
    Northover, John
    Silver, Andrew
    INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (12) : 2668 - 2673
12345